At a glance
ClinicalIndex Comparison RecordN/ACompleted· 500 enrolled
Drug / intervention
PROMUS Element Coronary Stent System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PLATINUM China: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion
In Brief
A clinical study evaluating PROMUS Element Coronary Stent System and TAXUS Liberté Coronary Stent System for Atherosclerosis and Coronary Artery Disease. Completed, enrolled 500 participants across 15 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS™ Element™ Everolimus-Eluting Coronary Stent System for the treatment of subjects in China with a single de novo atherosclerotic coronary artery lesion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis, Coronary Artery Disease
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionMar 2013
Study CompletionAug 2014
TodayJul 2026
First PostedJan 31, 2011
Enrollment StartJan 1, 2011
Primary CompletionMar 1, 2013
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.4 years ago
Interventions
PROMUS Element Coronary Stent Systemdevice
Everolimus-eluting Coronary Stent Drug-eluting Stent (DES) implantation
TAXUS Liberté Coronary Stent Systemdevice
Paclitaxel-eluting Coronary Stent Drug-eluting Stent (DES) implantation